LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | XMD16-144 | 0.12 | uM | LJP5 | 72 | hr | 1334 | 2327 | 4033 | 0.5777 | 0.4173 |
BT-20 | XMD16-144 | 0.37 | uM | LJP5 | 72 | hr | 1334 | 1362 | 4033 | 0.3385 | 0.0129 |
BT-20 | XMD16-144 | 1.11 | uM | LJP5 | 72 | hr | 1334 | 1159 | 4033 | 0.2874 | -0.0848 |
BT-20 | XMD16-144 | 3.33 | uM | LJP5 | 72 | hr | 1334 | 1214 | 4033 | 0.3013 | -0.0575 |
BT-20 | XMD16-144 | 10 | uM | LJP5 | 72 | hr | 1334 | 818 | 4033 | 0.2030 | -0.2640 |
BT-20 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1334 | 3679 | 4033 | 0.9124 | 0.8880 |
BT-20 | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 1334 | 3804 | 4033 | 0.9435 | 0.9287 |
BT-20 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1334 | 3961 | 4033 | 0.9819 | 0.9769 |
BT-20 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 1334 | 3554 | 4033 | 0.8814 | 0.8480 |
BT-20 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1334 | 3753 | 4033 | 0.9304 | 0.9114 |
BT-20 | Erlotinib | 10 | uM | LJP5 | 72 | hr | 1334 | 2541 | 4033 | 0.6312 | 0.4971 |
BT-20 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1334 | 4187 | 3925 | 1.0668 | 1.0848 |
BT-20 | Gefitinib | 0.12 | uM | LJP6 | 72 | hr | 1334 | 4099 | 3925 | 1.0441 | 1.0551 |
BT-20 | Gefitinib | 0.37 | uM | LJP6 | 72 | hr | 1334 | 3831 | 3925 | 0.9760 | 0.9685 |
BT-20 | Gefitinib | 1.11 | uM | LJP6 | 72 | hr | 1334 | 3848 | 3925 | 0.9802 | 0.9739 |
BT-20 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 1334 | 3702 | 3925 | 0.9429 | 0.9247 |
BT-20 | Gefitinib | 10 | uM | LJP6 | 72 | hr | 1334 | 3574 | 3925 | 0.9103 | 0.8822 |
BT-20 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4101 | 4033 | 1.0178 | 1.0212 |
BT-20 | Nilotinib | 0.12 | uM | LJP5 | 72 | hr | 1334 | 4116 | 4033 | 1.0214 | 1.0269 |
BT-20 | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 1334 | 4227 | 4033 | 1.0488 | 1.0610 |
BT-20 | Nilotinib | 1.11 | uM | LJP5 | 72 | hr | 1334 | 4129 | 4033 | 1.0244 | 1.0304 |
BT-20 | Nilotinib | 3.33 | uM | LJP5 | 72 | hr | 1334 | 4174 | 4033 | 1.0358 | 1.0451 |
BT-20 | Nilotinib | 10 | uM | LJP5 | 72 | hr | 1334 | 1233 | 4033 | 0.3063 | -0.0480 |
BT-20 | JNK-9L | 0.04 | uM | LJP6 | 72 | hr | 1334 | 3521 | 3925 | 0.8968 | 0.8643 |
BT-20 | JNK-9L | 0.12 | uM | LJP6 | 72 | hr | 1334 | 3619 | 3925 | 0.9224 | 0.8985 |